Physician profile
Yuefeng Chen
NPI 1467700716
$4,878.89
in general payments reported to CMS, 2019-2025
27 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $1,814 · 2021: $75.09 · 2022: $930 · 2023: $329 · 2024: $599 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,938.56 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $437.67 | 2021-2025 | Lifevest |
| Abiomed | $413.82 | 2021-2024 | Impella |
| Boston Scientific Corporation | $328.56 | 2019-2022 | |
| Cardiovascular Systems INC. | $280.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $261.47 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $238.40 | 2024-2025 | |
| Abbott Laboratories | $154.07 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $127.83 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $91.27 | 2022-2023 | Eliquis |
| Pfizer INC. | $75.45 | 2022-2025 | |
| Scpharmaceuticals INC. | $71.98 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $68.31 | 2022-2024 | Opsumit, Uptravi |
| Cook Medical LLC | $60.55 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $50.03 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $44.57 | 2019-2025 | Extended Holter |
| W. L. Gore & Associates, INC. | $38.24 | 2019 | |
| Amgen INC. | $34.58 | 2023 | Repatha |
| Novo Nordisk INC | $32.72 | 2023-2024 | Ozempic, Rybelsus |
| Teleflex LLC | $19.84 | 2025 | Trapliner |
| Terumo Medical Corporation | $19.71 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $16.36 | 2024 | |
| Medtronic, INC. | $15.90 | 2024 | Cobalt Dr Mri Surescan |
| Amarin Pharma, INC. | $15.14 | 2022 | |
| Bridgebio Pharma, INC. | $14.92 | 2025 | Attruby |
| Medicomp INC | $14.59 | 2025 | Telepatch Cardiac Monitor |
| Merck Sharp & Dohme LLC | $13.41 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuefeng Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.